New Treatments for the Management of Treatment-Experienced Breast Cancer: Examining the Evidence
Including proceedings from a roundtable held in Scottsdale, Arizona.
Activity Date: December 2007  — Activity Info: Volume4, (13)
Goals & Objectives | Faculty | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired)


To provide hospital, managed care, and oncology pharmacists with up-to-date information regarding their role in managing the treatment of patients with breast cancer.

This activity is designed for hospital, managed care, and oncology pharmacists. No prerequisites required.

The University of Tennessee College of Pharmacy takes responsibility for the
content, quality, and scientific integrity of this CE activity. At the conclusion of this activity, the participant should be able to:

  • Summarize the results of recent clinical trials investigating US Food and Drug Administration-approved and investigational agents for treatment-resistant breast cancer.
  • Examine the unique mechanism of action and activity of epothilones in treatment-resistant tumors.
  • Describe the potential adverse effects of epothilones and develop strategies to effectively communicate the potential risks and benefits of treatment to patients.
  • Evaluate the results of recent studies on molecular profiling of breast cancer, and consider how these tools may be used to determine the best treatment options for patients with breast cancer.
  • Discuss the role of the oncology pharmacist in improving therapeutic strategies and further enhancing the outcomes of patients with breast cancer.

The University of Tennessee College of Pharmacy (UTCOP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) to provide continuing education for pharmacists.

This program is approved for 2 hours of credit (0.2 CEUs) and is sponsored by the University of Tennessee College of Pharmacy, which is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To receive a statement of CE credit, the participant must complete the program and participant evaluation form at the conclusion of the program. Statements of CE credit can be printed online after successfully completing the program.

ACPE Program #064-000-07-217-H01-P

This continuing education activity was produced under the supervision of
Glen E. Farr, PharmD, Associate Dean of Continuing Pharmacy Education, University of Tennessee College of Pharmacy.

The estimated time to complete this educational activity:  2 hours.

Release date: December 15, 2007. Expiration date: December 15, 2009.

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.

This program is supported by an educational grant from Bristol-Myers Squibb.

Home | Contact Us | View Account | Need Help?